ProCE Banner Activity

2022 ASH Annual Meeting: Expert Discussion of New Agents for Follicular Lymphoma

Clinical Thought

Gain expert perspective on the most clinically relevant data in follicular lymphoma presented at the 2022 ASH Annual Meeting, including bispecific antibodies, an EZH2 inhibitor, and considerations for selecting patients for CAR T-cell therapy.

Released: February 17, 2023

Expiration: February 16, 2024

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Genentech, a member of the Roche Group

Program Director Disclosure

Program Director

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD: consultant: Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol-Myers Squibb, Epizyme, Kura, Kymera, MorphoSys, Novartis, Nurix, Roche/Genentech, SeaGen, TG Therapeutics, Verastem, X4 Pharmaceuticals; speaker: BeiGene, SeaGen; researcher: MorphoSys.